What you need to know ### BMJ Learning To obtain accredited continuous professional development points, subscribers to BMJ Learning can complete the full module at The module contains four additional ...

Both allopurinol and febuxostat carry similar, significant increased risks for hypersensitivity reactions compared with colchicine, according to data published in Annals of the Rheumatic Diseases.

Matched cohort studies revealed infrequent adverse events (AEs) with either treatment, but the number needed to harm for any AE was more than three times higher with colchicine vs NSAIDs. The ...

Choi notes that many of these lifestyle changes will not only reduce uric acid levels and the risk of recurrent gout but will also improve the health status of those with comorbidities, particularly ...

Dr. Keith Roach writes a medical question-and-answer column weekdays. Dear Dr. Roach: I am a 71-year-old woman recently diagnosed with gout. I have been put on colchicine and allopurinol. Are these ...

The comparative efficacy of these therapies has been extended to patients with stage 3 chronic kidney disease, a common comorbidity in gout. Allopurinol and febuxostat are similarly effective in ...

100% Response Rate Achieved with All Doses of RDEA594 Combined with Febuxostat or Allopurinol; Serum Uric Acid Levels Reduced by Up to 80% SAN DIEGO, Nov. 8, 2010 ...

Trial subgroup analyses support the use of either allopurinol or febuxostat in patients with stage 3 CKD and gout. A prespecified analysis of the STOP-GOUT trial revealed that allopurinol has similar ...

Over the years, gout has grown in clinical complexity. We see many more cases with iatrogenic factors, multiple comorbidities, advanced age and treatment-refractory hyperuricemia and arthritis (Table ...

A gout drug has been approved by the FDA, the first in 40 years, with three more in the wings. What accounts for this sudden slew of gout therapies? Jill U. Adams investigates. On February 16, the US ...